Junik R, Sowiński J, Zamysłowska H, Gembicki M
Endokrynol Pol. 1989;40(6):307-13.
The effectiveness of therapy involving intravenous administration of methimazole applied in patients with hyperthyroidism resistant to oral thyrostatic drugs has been investigated. Methimazole (Favistan, Asta) was administered intravenously to 3 patients (two women and one man, of ages 21, 24 and 67 years, respectively) in whom there was no remission of the disease after oral methimazole therapy lasting at least two months. Blood serum concentrations of thyroxine (T4), triiodothyronine (T3), reverse++ triiodothyronine (rT3) and triiodothyronine binding index (T3I) have been measured and free thyroxine index (FT4I) calculated before the treatment and on the 4-th, 7-th, 11-th, 14-th and 17-th day of the treatment. The mean value of T4 concentration decreased from 17.0 micrograms/dl before the treatment to 9.7 micrograms/dl after the treatment. T3 from 352 to 177 ng/dl, rT3 from 114 to 103ng/dl the value of T3I from 183 to 161%, and that of FT4I from 30 to 17, respectively. A significant fall of T3 level was observed on the 11-th day of the therapy, that of rT3 on the 14-th day, and that of FT4I on the seventh day. It was concluded that the resistance of some patients with hyperthyroidism to the oral thyreostatic therapy may be caused by the defective absorption of these drugs from the intestinal tract.
对静脉注射甲巯咪唑治疗口服抗甲状腺药物耐药的甲状腺功能亢进症患者的疗效进行了研究。对3例患者（2例女性，1例男性，年龄分别为21岁、24岁和67岁）静脉注射甲巯咪唑（法维斯坦，阿斯塔），这些患者在持续口服甲巯咪唑治疗至少两个月后病情仍未缓解。在治疗前以及治疗的第4天、第7天、第11天、第14天和第17天，测量了血清甲状腺素（T4）、三碘甲状腺原氨酸（T3）、反三碘甲状腺原氨酸（rT3）和三碘甲状腺原氨酸结合指数（T3I），并计算了游离甲状腺素指数（FT4I）。T4浓度的平均值从治疗前的17.0微克/分升降至治疗后的9.7微克/分升。T3从352纳克/分升降至177纳克/分升，rT3从114纳克/分升降至103纳克/分升，T3I值从183%降至161%，FT4I值从30降至17。在治疗的第11天观察到T3水平显著下降，第14天观察到rT3水平下降，第7天观察到FT4I水平下降。得出结论，一些甲状腺功能亢进症患者对口服抗甲状腺治疗耐药可能是由于这些药物在肠道的吸收不良所致。
